Tarsus Pharmaceuticals, Inc.
TARS
$69.28
$1.321.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 27.78% | 15.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 27.78% | 15.62% | |||
| Cost of Revenue | 17.77% | 12.65% | |||
| Gross Profit | 30.39% | 16.42% | |||
| SG&A Expenses | 20.30% | 5.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.83% | 6.71% | |||
| Operating Income | 45.10% | 34.51% | |||
| Income Before Tax | 49.83% | 38.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.47% | 38.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.47% | 38.13% | |||
| EBIT | 45.10% | 34.51% | |||
| EBITDA | 46.46% | 35.26% | |||
| EPS Basic | 33.75% | 38.48% | |||
| Normalized Basic EPS | 86.08% | 38.49% | |||
| EPS Diluted | 33.75% | 38.48% | |||
| Normalized Diluted EPS | 86.08% | 38.49% | |||
| Average Basic Shares Outstanding | 0.42% | 0.58% | |||
| Average Diluted Shares Outstanding | 0.42% | 0.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||